Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Hepatology. 2016 Jul 30;64(4):1202–1216. doi: 10.1002/hep.28704

Figure 3.

Figure 3

(A) Liver damage was assessed by H&E staining in liver sections from all groups. Inflammation, necrosis and lobular damage increased in Mdr2−/− mice compared to WT mice and these features were reduced in Mdr2−/− mice treated with cromolyn sodium. Images are 20× magnification. (B) Liver weight and body weights were recorded for each animal and the ratio was calculated. Mdr2−/− mice have increased liver/BW ratio compared to WT and treatment with cromolyn sodium significantly decreases liver/BW ratio compared to Mdr2−/−. (C) Bile duct mass and (D) Ki-67 were evaluated in liver sections from WT, Mdr2−/− mice and Mdr2−/− mice treated with cromolyn sodium. We found that bile duct mass (CK-19 staining, red arrows) and Ki-67 increased in Mdr2−/− mice compared to WT mice, whereas treatment with cromolyn sodium decreased both bile duct mass (red arrows) and the number of proliferating cholangiocytes (green arrows). Data has been semi-quantitated. Data are expressed as mean ± SEM of at least 10 experiments. *p<0.05 versus WT mice; #p<0.05 versus Mdr2−/− mice.